MarketCap
Verrica Pharmaceuticals VRCA
$ 3.55
-1.39%
Facebook
X
Telegram
Verrica Pharmaceuticals Operating Cycle | VRCA
Annual Operating Cycle Verrica Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.2 | 348 | 524 | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 524 | 27.2 | 300 |
Quarterly Operating Cycle Verrica Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 51.7 | 53.2 | 396 | - | - | 489 | 364 | - | 104 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 489 | 51.7 | 243 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Sesen Bio
SESN
|
391 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
164 | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
25.5 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
392 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
6.22 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
107 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B |  Niderland |
 |
AbbVie
ABBV
|
350 | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
86.7 | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
33.4 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Axon Enterprise
AXON
|
98.8 | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
456 | - | - | $ 83.9 M |  Canada |
 |
Liquidia Corporation
LQDA
|
36.8 | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
153 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
Celldex Therapeutics
CLDX
|
43.4 | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
233 | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
361 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
433 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
554 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mesoblast Limited
MESO
|
0.01 | $ 14.0 | -3.06 % | $ 16.9 B |  Australia |
 |
CorMedix
CRMD
|
439 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.1 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
457 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
263 | - | - | $ 521 M | USA |
 |
Merck & Co.
MRK
|
204 | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
108 | $ 250.79 | -6.77 % | $ 97.6 B | USA |